CPHI & PMEC China Sees Surge in Global Pharma Attendance
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth CPHI & PMEC China returns to the Shanghai...
Category : Clinical Research, Pharma & Healthcare Financing
Foundation Medicine Adds MET Testing to IHC Portfolio
Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC...
PeproMene, IFLI: First FL Patient on BAFF-R CAR-T Sees Complete Response
PeproMene Bio, Inc. (PMB) a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first r/r FL patient treated...
XellSmart’s iPSC Therapy for Spinal Injury Approved for FDA Trial
In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both China’s National...
GIG Gulf Secures Category “A” Health License in Oman
GIG Gulf has achieved a landmark milestone in Oman, becoming one of the first insurers to be awarded a Category “A” license by the Financial Services...
Dizal to Present Cancer Drug Advances at ASCO 2025
Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will present latest clinical...
Millions at Risk: Komen Speaks Out Against House Reconciliation Bill
Breast cancer patients could lose coverage, face delays in critical care Susan G. Komen, the world’s leading nonprofit breast cancer organization, is deeply troubled by...
Celltrion’s YUFLYMA® Receives FDA Interchangeability Designation
Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA® (adalimumab-aaty), now including prefilled syringe (40mg)...
AnnJi Pharma Announces Positive Phase 1/2a Results for AJ201
AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results...
Ascletis Announces FDA Clearance for ASC50 Psoriasis Trial
ASC50 is an in-house discovered and developed oral small molecule interleukin-17 (IL-17) inhibitor for the treatment of multiple autoimmune and inflammatory diseases, including psoriasis. Following...
ZEVTERA Now Available in U.S. to Treat MRSA Infections
ZEVTERA is the first and only U.S. Food and Drug Administration-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia (SAB), including right-sided endocarditis, caused by the methicillin-resistant Staphylococcus aureus (MRSA)....
Pulnovo Gains EQT Investment After CE-MDR Approval
Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has received new investment from EQT Group, a...
Abzena Establishes Scientific Advisory Board for Innovation Strategy
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of...
Rznomics Partners with Eli Lilly for RNA-editing Therapeutics Licensing
Co-development of precision RNA therapeutics for inherited hearing loss treatment Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has...
ArkBio Announces Positive Phase II Results for AK3280 in IPF Treatment
Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF)....